CoChat

Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab

Levin, Victor A., Chan, James, Datta, Meenal, Yee, Jennie L., Jain, Rakesh K. · 2017 · Journal of Neuro-Oncology

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM). Of the 1186 glioma patients who received chemotherapy ASI exposure improved OS (HR 0.82; 95% CI 0.71, 0.93; p = 0.003). When stratified by BEV exposure, a sub-analysis revealed further OS advantage for the BEV group (HR 0.75, 95% CI 0.62, 0.90; p = 0.002). In a second cohort of 181 rGBM patients who received BEV in varying dosages, ASI exposure conferred an OS advantage (HR 0.649; 95% CI 0.46, 0.92; p = 0.016). Moreover, patients with ASI exposure who received low-dose BEV treatment (AUC BEV < 3.6 mg wk/kg) had a significantly longer OS (median = 99 weeks; 95% CI 44.3, 205) than those without ASI (median OS = 55.6 weeks; 95% CI 37.7-73.7; p = 0.032). ASI use is associated with longer OS in glioma patients. Further survival advantage with ASI use was observed in rGBM patients receiving low-dose bevacizumab. These data warrant prospective evaluation of adding ASI to low-dose BEV treatment in GBM patients to improve the outcome of standard therapies.

Overview

Integrity signals

Registry

Crossref · 10.1007/s11060-017-2528-3

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. Lu-Emerson C, Duda DG, Emblem KE, Taylor JW, Gerstner ER, Loeffler JS, Batchelor TT, Jain RK (2015) Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J Clin Oncol 33:1197–1213. doi: 10.1200/JCO.2014.55.9575 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Levin, V. A., Chan, J., Datta, M., Yee, J. L., & Jain, R. K.
Affiliations
  • Kaiser Permanente (US)
  • Tufts University (US)
  • Harvard University (US)
Corresponding author
Levin, Victor A.
Venue
Journal of Neuro-Oncology
Published
2017-06-19
Volume
134
Issue
2
Pages
325-330
ISSN
  • 0167-594X (ISSN-L)
  • 1573-7373
OpenAlex
W2655050774
Cited by
51
References
24
Citations by year
2026: 1 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 8 · 2017: 1
FWCI
3.61
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Neuro-Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institutes of Health (P01CA080124, NIH-F31HL126449)
Topics
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords
renin-angiotensin system inhibitors, glioma, glioblastoma, recurrent glioblastoma, bevacizumab, overall survival, low-dose bevacizumab, cytotoxic chemotherapy, combination therapy
MeSH terms
Bevacizumab, Antineoplastic Agents, Immunological, Adult, Aged, Brain Neoplasms, Drug Therapy, Combination, Female, Glioma, Humans, Male, Neoplasm Recurrence, Local, Registries, Retrospective Studies, Proportional Hazards Models, Angiotensin Receptor Antagonists, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. https://app.cochat.ai/papers/10.1007/s11060-017-2528-3
The paper
Levin, V. A., Chan, J., Datta, M., Yee, J. L., & Jain, R. K. (2017). Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-017-2528-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.